Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
39.1 HKD | +2.22% | +2.23% | -16.06% |
04/06 | Akeso Expands Territory of License Agreement for Lung Cancer Drug | MT |
03/06 | Summit Therapeutics Inc. Expands License Territories for Ivonescimab | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.06% | 4.24B | |
+16.45% | 123B | |
+21.96% | 115B | |
+23.73% | 25.85B | |
-20.05% | 20.9B | |
-16.28% | 16.77B | |
-16.52% | 16.52B | |
-44.35% | 15.56B | |
+63.91% | 15.49B | |
+2.52% | 13.45B |
- Stock Market
- Equities
- 9926 Stock
- News Akeso, Inc.
- Akeso Lung Cancer Drug Gets NMPA's Marketing Approval; Stocks Crash 20%